PB
PBLA.US Panbela Therapeutics Inc
- Market cap
- USD 970.00
- P/E
- -
- P/B
- 3.22x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2024.
Is PBLA.US undervalued?
Graham numberThe Graham number of Panbela Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Panbela Therapeutics Inc fundamental analysis
No fundamental analysis for Panbela Therapeutics Inc yet.
Panbela Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Panbela Therapeutics Inc
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac whic…
Full company profilePanbela Therapeutics Inc financial statements
2024 annualized: Fiscal year 2024 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2024, the balance sheet is the latest quarter. Figures change when the annual report is published.
Panbela Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.36M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.64M | 0.00 | 0.00 |
| Gross Profit | 762K | -5.44M | -5.17M | -6.02M | -3.89M | -4.32M | -5.75M | -10.0M | -35.7M | -25.6M | -29.3M |
| Operating Income | -75.4K | -5.44M | -5.17M | -6.02M | -3.89M | -4.32M | -5.75M | -10.0M | -34.1M | -51.3M | -38.9M |
| EBITDA | -75.4K | -5.47M | -5.25M | -7.85M | -2.60M | -2.34M | -4.93M | -602K | -18.4M | -25.8M | -26.6M |
| Net Income | -107K | -4.93M | -5.11M | -10.4M | -5.91M | -6.20M | -4.77M | -10.1M | -34.9M | -25.3M | -28.6M |
| EPS | -892 | -4,204 | -1,975 | -3,492 | -1,520 | -26,050 | -14,807 | -20,768 | -40,762 | -8.08 | -5.89 |
| Balance Sheet | |||||||||||
| Total Assets | 407K | 1.81M | 877K | 767K | 1.90M | 3.14M | 9.81M | 12.9M | 4.98M | 11.8M | 5.17M |
| Total Liabilities | 618K | 4.49M | 5.52M | 4.46M | 1.63M | 1.76M | 1.37M | 2.66M | 13.0M | 16.5M | 23.3M |
| Shareholders' Equity | -211K | -2.68M | -4.64M | -3.69M | 268K | 1.39M | 8.45M | 10.2M | -8.05M | -4.71M | -18.2M |
| Cash & Short-term Investments | 164K | 925K | 438K | 152K | 1.41M | 2.45M | 9.02M | 11.9M | 1.29M | 2.58M | 142K |
| Total Debt | 577K | 3.33M | 3.28M | 1.83M | 350K | 116K | - | - | 6.84M | 5.19M | 6.39M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -11.5K | -3.90M | -2.40M | -3.40M | -2.39M | -2.74M | -3.85M | -6.70M | -15.3M | -25.2M | -16.7M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 660K | 0.00 | 0.00 |
| Free Cash Flow | -11.5K | -3.90M | -2.40M | -3.40M | -2.39M | -2.74M | -3.85M | -6.70M | -15.9M | -25.2M | -16.7M |
| Ratios | |||||||||||
| ROE | - | - | - | - | -2,203.4% | -447.7% | -56.4% | -99.2% | - | - | - |
| ROA | -26.3% | -272.5% | -582.9% | -1,352.5% | -311.1% | -197.2% | -48.6% | -78.7% | -701.7% | -214.1% | -552.9% |
| Net Profit Margin | -7.9% | - | - | - | - | - | - | - | - | - | - |
| Debt to Equity | - | - | - | - | 1.31x | 0.08x | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Panbela Therapeutics Inc dividends
Panbela Therapeutics Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:20 on Jan 18, 2024.
Who owns Panbela Therapeutics Inc
- Insiders 0.00%
- Institutions 0.00%
- Public & others 100.00%
- Shares outstanding 4.85M
- Free float 4.85M
Top funds holding PBLA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Parametric Tax-Managed Emerg Mkt I | 35.3K | 0.73% | 0.00% | Jan 2025 |
| Parametric Emerging Markets I | 17.3K | 0.36% | 0.00% | Jan 2025 |
Top institutions holding PBLA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Citadel Advisors Llc | 0.00 | 0.00% | -100.00% | Jun 2024 |
Panbela Therapeutics Inc company profile
- Company name
- Panbela Therapeutics Inc
- Ticker
- PBLA.US
- Exchange
- USA Stocks
- Listed since
- Jan 3, 2017
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 7
- Fiscal year end
- December
- Address
- 712 Vista Boulevard, Waconia, MN, United States, 55387
- Phone
- 952 479 1196
- Website
- panbela.com
About Panbela Therapeutics Inc
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
Panbela Therapeutics Inc management
3- Dr. Jennifer K. Simpson CRNP, M.S.N., Ph.D.CEO, President & Director · born 1968
- Ms. Susan HorvathVP of Finance, CFO, Secretary & Treasurer · born 1959
- Ms. Tammy GroeneVice President of Operations